PRESTALIA Drug Patent Profile

When do Prestalia patents expire, and what generic alternatives are available?

Prestalia is a drug marketed by Adhera and is included in one NDA. There is one patent protecting this drug and one Paragraph IV challenge.

This drug has thirty patent family members in twenty-seven countries.

The generic ingredient in PRESTALIA is amlodipine besylate; perindopril arginine. There are fifty drug master file entries for this compound. Additional details are available on the amlodipine besylate; perindopril arginine profile page.

DrugPatentWatch^® Generic Entry Outlook for Prestalia

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be October 5, 2029. This may change due to patent challenges or generic licensing.

There is one Paragraph IV patent challenge for this drug. This may lead to patent invalidation or a license for generic production.

Indicators of Generic Entry

Summary for PRESTALIA

International Patents:	30
US Patents:	1
Applicants:	1
NDAs:	1
Raw Ingredient (Bulk) Api Vendors:	1
Patent Applications:	2
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for PRESTALIA
What excipients (inactive ingredients) are in PRESTALIA?	PRESTALIA excipients list
DailyMed Link:	PRESTALIA at DailyMed

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for PRESTALIA

NDA:

205003

Dosage:

TABLET;ORAL

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Paragraph IV (Patent) Challenges for PRESTALIA

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
PRESTALIA	Tablets	amlodipine besylate; perindopril arginine	3.5 mg/2.5 mg, 7 mg/5 mg and 14 mg/10 mg	205003	1	2016-11-04

US Patents and Regulatory Information for PRESTALIA

PRESTALIA is protected by one US patents.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Adhera	PRESTALIA	amlodipine besylate; perindopril arginine	TABLET;ORAL	205003-001	Jan 21, 2015		DISCN	Yes	No			Y	Y
Adhera	PRESTALIA	amlodipine besylate; perindopril arginine	TABLET;ORAL	205003-002	Jan 21, 2015		DISCN	Yes	No			Y	Y
Adhera	PRESTALIA	amlodipine besylate; perindopril arginine	TABLET;ORAL	205003-003	Jan 21, 2015		DISCN	Yes	No			Y	Y

Expired US Patents for PRESTALIA

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Adhera	PRESTALIA	amlodipine besylate; perindopril arginine	TABLET;ORAL	205003-001	Jan 21, 2015
Adhera	PRESTALIA	amlodipine besylate; perindopril arginine	TABLET;ORAL	205003-003	Jan 21, 2015
Adhera	PRESTALIA	amlodipine besylate; perindopril arginine	TABLET;ORAL	205003-002	Jan 21, 2015

International Patents for PRESTALIA

When does loss-of-exclusivity occur for PRESTALIA?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

Australia

European Patent Office

Georgia, Republic of

Hungary

Morocco

Norway

Poland

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering PRESTALIA around the world.

Country	Patent Number	Title	Estimated Expiration
African Regional IP Organization (ARIPO)	1787	Novel perindopril salt and pharmaceutical compositions containing same.
Argentina	039428	SAL DE PERINDOPRIL Y COMPOSICIONES FARMACEUTICAS QUE LAS CONTIENEN
Austria	271036
Australia	2003200700
Australia	2003222921	NOVEL PERINDOPRIL SALT AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME
Brazil	0300709	Sal de perindopril e as composições farmacêuticas contendo o mesmo

Supplementary Protection Certificates for PRESTALIA

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
0443983	C300445	Netherlands		PRODUCT NAME: VALSARTAN, AMLODIPINE EN HYDROCHLOORTHIAZIDE EN FARMACEUTISCH AANVAARDBARE ZOUTEN DAARVAN; REGISTRATION NO/DATE: EU/1/09/569/001-060 20091016
0443983	C00443983/03	Switzerland		PRODUCT NAME: VALSARTAN + AMLODIPINE + HYDROCHLOROTHIAZIDE; REGISTRATION NUMBER/DATE: SWISSMEDIC 59407 16.09.2009
0443983	2007C/043	Belgium		PRODUCT NAME: AMLODIPINE ET VALSARTAN; NATL. REGISTRATION NO/DATE: EU/1/06/370/001 20070118; FIRST REGISTRATION: CH 57771 20061222
0502314	C300478	Netherlands		PRODUCT NAME: TELMISARTAN, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAARDBAAR ZOUT, EN AMLODIPINE, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAARDBAAR ZOUT, IN HET BIJZONDER AMLODIPINEBESILAAT; REGISTRATION NO/DATE: EU/1/10/648/001-028 20101007
0502314	SPC/GB11/010	United Kingdom		PRODUCT NAME: THE COMBINATION OF A) TELMISARTAN, OPTIONALLY IN THE FORM OF PHARMACEUTICALLY ACCEPTABLE SALTS, AND B) AMLODIPINE, OPTIONALLY IN THE FORM OF PHARMACEUTICALLY ACCEPTABLE SALTS, ESPECIALLY AMLODIPINE BESYLATE; REGISTERED: UK EU/1/10/648/001 20101007; UK EU/1/10/648/002 20101007; UK EU/1/10/648/003 20101007; UK EU/1/10/648/004 20101007; UK EU/1/10/648/005 20101007; UK EU/1/10/648/006 20101007; UK EU/1/10/648/007 20101007; UK EU/1/10/648/008 20101007; UK EU/1/10/648/009 20101007; UK EU/1/10/648/010 20101007; UK EU/1/10/648/011 20101007; UK EU/1/10/648/012 20101007; UK EU/1/10/648/013 20101007; UK EU/1/10/648/014 20101007; UK EU/1/10/648/015 20101007; UK EU/1/10/648/016 20101007; UK
0503785	C300486	Netherlands		PRODUCT NAME: COMBINATIE VAN OLMESARTANMEDOXOMIL, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAARDBAAR ZOUT, AMLODIPINEBESYLAAT AND HYDROCHLOORTHIAZIDE; NATL REGISTRATION NO/DATE: RVG 106667, RVG 106671-74, RVG 106682-86 20101221; FIRST REGISTRATION: DE 79810.00.00-79814.00.00 20101216

Prestalia (Prednisone) Market Dynamics and Financial Trajectory: exclusivity, competitive pressure, and commercialization outlook

Last updated: July 30, 2026

How has Prestalia’s market performance tracked since launch?

Answer: Prestalia’s commercial trajectory depends on whether it is treated as a prednisone brand launch with localized demand capture or as a substitute within a narrower corticosteroid segment, with financial outcomes driven by payer coverage, formulary placement, and the speed of generic or therapeutic substitution.

What product is “Prestalia” in commercial terms?

• Drug identity: “Prestalia” is used as a brand name for prednisolone/prednisone-type corticosteroid therapy in multiple markets. Commercial performance is highly jurisdiction-specific because pricing and access rules differ by country.
• Key commercial drivers: net price after rebates, volume uptake in target indications, and whether clinicians substitute to cheaper generics before payer step edits tighten.

What typically moves corticosteroid brand revenue in the real world?

Corticosteroid branded revenue is usually a function of:

• Formulary inclusion (national preferred vs. non-preferred)
• Switching dynamics (fast uptake of generics when available)
• Stewardship limits (step therapy, prior authorization, quantity limits)
• Channel mix (hospital vs. retail and how each is reimbursed)
• Indication breadth (broad chronic use stabilizes, narrow acute use compresses)

What patents protect Prestalia, and when do they expire?

Answer: Prestalia’s long-run economics hinge on whether a meaningful patent estate survives beyond the earliest generic entry dates. Without the specific active ingredient variant (e.g., prednisone vs prednisolone), strength, dosage form, and jurisdiction, a complete and accurate patent calendar cannot be constructed.

Why patent coverage determines financial trajectory

• If exclusivity/patents end early, net revenue typically falls sharply after generic competitive entry.
• If patents cover a formulation, manufacturing method, or controlled-release profile, delayed generic substitution can preserve price for longer.

When does Prestalia lose exclusivity or face generic entry risk?

Answer: Generic entry risk tracks the earliest of:

• patent expiration for the active pharmaceutical ingredient and/or key formulation,
• expiration of any regulatory exclusivity (where applicable),
• and the timing of market entry of authorized generics or competing brands.

How to model the revenue impact once exclusivity ends

A practical model for corticosteroid brand revenue:

• Pre-entry: stable units with rebate pressure
• Entry year: fast unit decline with price compression
• Post-entry: residual demand for prescriber preference, contracting status, and supply continuity

What is the Orange Book status of Prestalia, and are there Paragraph IV challenges?

Answer: Orange Book status and Paragraph IV exposure require the specific FDA application listing (active ingredient, strength, dosage form, and NDA/BLA number). Without that identifier, the exclusivity and litigation landscape cannot be reported accurately.

Which generic or biosimilar competitors affect Prestalia pricing and volume?

Answer: Prestalia faces pressure from:

• generic prednisone/prednisolone products (same active ingredient),
• and therapeutic alternatives (other corticosteroids) where payer policies allow interchangeability.

What changes after generic entry?

• Net price often drops most quickly when payers can dispense at the lowest AWP-based tier.
• Patient retention depends on:
  • prescriber inertia,
  • contracting to preferred generics,
  • and whether any remaining patents block “AB-rated” substitution.

How strong is the patent estate for Prestalia compared with peers?

Answer: The strength and breadth of Prestalia’s patent estate cannot be assessed without mapping:

• all listed patents (composition, method-of-use, formulation, and process),
• their expiration dates,
• and whether they cover the exact strengths/dosage forms sold.

What formulations are protected for Prestalia, and what does that mean commercially?

Answer: If the sold product is protected by formulation or process patents, competitors face higher development and regulatory hurdles, which can slow volume loss after initial generic threats. If only the active ingredient is protected, entry barriers are lower and price compression accelerates.

Typical patent-formulation patterns that matter

• particle engineering and dissolution profile (where applicable)
• excipient and coating systems
• manufacturing process controls
• stability/packaging patents tied to shelf life

What patent litigation affects Prestalia’s commercialization?

Answer: Litigation risk is product- and jurisdiction-specific. A complete litigation timeline requires:

• the case dockets or publicly reported filings,
• and the asserted patents with jurisdictions.

What FDA regulatory pathway does Prestalia use, and does that impact its exclusivity?

Answer: The FDA pathway (NDA vs ANDA for the product category) affects exclusivity mechanics. For an accurate trajectory, the specific FDA application and exclusivity codes tied to the product are required.

How do licensing deals or settlements influence Prestalia’s financial trajectory?

Answer: Settlement terms can determine:

• launch timing for challengers,
• marketing scope (label limitations, dosage form restrictions),
• and royalty or consideration structures. A settlement-driven forecast requires the named parties, patents asserted, and jurisdictional terms.

Prestalia vs. other corticosteroid brands: where does it win and lose?

Answer: Without the specific market and molecule identity, Prestalia’s competitive positioning cannot be stated with accuracy.

The standard competitive axes for corticosteroids

• Net price vs. preferred generic tiers
• Formulary placement and tendering
• Switching policies and prior authorization
• Supply reliability and packaging attributes
• Clinical protocol fit (indication alignment)

What is the revenue exposure for Prestalia under different generic-launch scenarios?

Answer: Revenue exposure depends on the exclusivity end date and the expected speed of competitive substitution.

Scenario framework (generic entry timing)

• Early-entry scenario: revenue declines steeply in first 6 to 18 months after AB substitution.
• Delayed-entry scenario: revenue compression is slower; brand profitability depends on rebate leverage.
• Partial-protection scenario: competitors enter some strengths or dosage forms first, fragmenting unit demand.

Key business metrics that typically shift

• unit sales trajectory
• rebate rate and payer mix
• gross-to-net spread
• pharmacy benefit manager tiering and contract terms
• inventory drawdowns ahead of entry

Which market geographies are most likely to drive Prestalia’s financial outcomes?

Answer: Corticosteroid brand dynamics differ sharply by country due to:

• generic substitution regulations,
• reference pricing rules,
• and tender systems for hospital supply. A geography map requires the specific regulatory approvals and commercial rollout footprint.

Key Takeaways

• Prestalia’s financial trajectory is driven primarily by exclusivity timing, generic substitution speed, and payer contracting.
• For corticosteroids, brand revenue typically compresses quickly once AB-rated generic entry is possible and payer tiers shift.
• Building a defensible forecast requires linking Prestalia to the exact active ingredient variant, dosage form, strength, and jurisdictional regulatory identifiers to map the patent calendar, Orange Book status, and any Paragraph IV or settlement activity.

FAQs

1. How quickly do prednisone/prednisolone brands lose share after generic AB substitution?
2. What drives net price compression for corticosteroid brands under PBM contracting?
3. Do formulation patents for oral corticosteroids meaningfully delay generic entry?
4. How do prior authorization and step therapy change the revenue curve post-entry?
5. What litigation artifacts (settlements, licensing) most affect future launch timing?

References

1. FDA. Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. U.S. Food and Drug Administration.
2. FDA. Drug Approvals and Databases: Orange Book Exclusivity and Therapeutic Equivalence. U.S. Food and Drug Administration.